Skip to main content
OpenTrials

Clinical trial condition

Immunoproliferative Disorders

Explore clinical trials studying Immunoproliferative Disorders. Study availability and eligibility vary by location and protocol.

9,951 public trials 2,018 recruiting studies
Refine in advanced search Browse all conditions

Immunoproliferative Disorders trial results

Active, Not Recruiting

A Study to Evaluate the Safety and Efficacy of Glofitamab in Combination With Rituximab (R) Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Circulating Tumor (ct)DNA High-Risk Patients With Untreated Diffuse Large B-Cell Lymphoma

NCT04980222

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +5 more
Locations
  • City of Hope Comprehensive Cancer Center Duarte, California, United States
  • Stanford Cancer Center Stanford, California, United States
  • University of Iowa Iowa City, Iowa, United States
  • Washington University; Wash Uni. Sch. Of Med St Louis, Missouri, United States
View all 18 locations
View Trial Details
Active, Not Recruiting

A(B)VD Followed by Nivolumab as Frontline Therapy for Higher Risk Patients With Classical Hodgkin Lymphoma (HL)

NCT03033914

Conditions
Hemic and Lymphatic Diseases, Hodgkin Disease, Hodgkin Lymphoma, +7 more
Locations
  • Karmanos Cancer Institute Detroit, Michigan, United States
  • Memorial Sloan Kettering Basking Ridge Basking Ridge, New Jersey, United States
  • Hackensack Meridian Health Hackensack, New Jersey, United States
  • Memorial Sloan Kettering Monmouth Middletown, New Jersey, United States
View Trial Details
Active, Not Recruiting

A Study of Tazemetostat With Rituximab and Abbreviated Bendamustine in the Frontline Treatment of High Tumor Burden Follicular Lymphoma

NCT05551936

Conditions
Follicular Lymphoma, Hemic and Lymphatic Diseases, Immune System Diseases, +8 more
Locations
  • Northwestern University Chicago, Illinois, United States
  • University of Illinois Cancer Center Chicago, Illinois, United States
  • Rutgers Cancer Institute of New Jersey New Brunswick, New Jersey, United States
  • Ohio State University Comprehensive Cancer Center Columbus, Ohio, United States
View Trial Details
Active, Not Recruiting

Acalabrutinib, Venetoclax, and Obinutuzumab for Initial Therapy of CLL

NCT03580928

Conditions
Chronic Disease, Chronic Lymphocytic Leukemia (CLL), Disease Attributes, +14 more
Locations
  • Stamford Hospital/Bennett Cancer Center Stamford, Connecticut, United States
  • Beth Israel Deaconess Medical Center Boston, Massachusetts, United States
  • Dana Farber Cancer Institute Boston, Massachusetts, United States
  • Lifespan Cancer Institute Providence, Rhode Island, United States
View Trial Details

Related conditions